Sahir Sultan Alvi

Dr. Sahir Sultan Alvi

Medicine and Oncology, The University of Texas Rio Grande Valley, Edinburg, Texas, USA
orcid
Post Doctoral Fellow, South Texas Center of Excellence for C...

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
Sahir Sultan AlviSahir Sultan Alvi
Sahir Sultan Alvi
IAIrfan A. Ansari
Irfan A. Ansari
Imran KhanImran Khan
Imran Khan
JIJohar Iqbal
Johar Iqbal
MKM. Salman Khan
M. Salman Khan

1 December 2017 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
Sahir Sultan AlviSahir Sultan Alvi
Sahir Sultan Alvi
IAIrfan A. Ansari
Irfan A. Ansari
MAMohammad Kaleem Ahmad
Mohammad Kaleem Ahmad
JIJohar Iqbal
Johar Iqbal
MKM. Salman Khan
M. Salman Khan

7 November 2015 in Natural Product Research
Verified
Journal Article
Closed access
Sahir Sultan AlviSahir Sultan Alvi
Sahir Sultan Alvi
DIDanish Iqbal
Danish Iqbal
Saheem AhmadSaheem Ahmad
Saheem Ahmad
MKM. Salman Khan
M. Salman Khan
This study initially aimed to depict the molecular rationale evolving the role of lycopene in inhibiting the enzymatic activity of β-hydroxy-β-methylglutaryl-CoA (HMG-CoA) reductase via in vitro and in silico analysis. Our results illustrated that lycopene exhibited strong HMG-CoA reductase inhibitory activity (IC50 value of 36 ng/ml) quite better than pravastatin (IC50 = 42 ng/ml) and strong DPPH free radical scavenging activity (IC50 value = 4.57 ± 0.23 μg/ml) as compared to ascorbic acid (IC50 value = 9.82 ± 0.42 μg/ml). Moreover, the Ki value of lycopene (36 ng/ml) depicted via Dixon plot was well concurred with an IC50 value of 36 ± 1.8 ng/ml. Moreover, molecular informatics study showed that lycopene exhibited binding energy of −5.62 kcal/mol indicating high affinity for HMG-CoA reductase than HMG-CoA (ΔG: −5.34 kcal/mol). Thus, in silico data clearly demonstrate and support the in vitro results that lycopene competitively inhibit HMG-CoA reductase activity by binding at the hydrophobic portion of HMG-CoA reductase.

1 August 2020 in Life Sciences
Verified
Journal Article
Closed access
Parvej AhmadParvej Ahmad
Parvej Ahmad
Sahir Sultan AlviSahir Sultan Alvi
Sahir Sultan Alvi
DIDanish Iqbal
Danish Iqbal
MKM. Salman Khan
M. Salman Khan

1 June 2020 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
RNRabia Nabi
Rabia Nabi
Sahir Sultan AlviSahir Sultan Alvi
Sahir Sultan Alvi
MSMohammad Shafi Shah
Mohammad Shafi Shah
Saheem AhmadSaheem Ahmad
Saheem Ahmad
MFMohammad Faisal
Mohammad Faisal
MKM. Salman Khan
M. Salman Khan

1 April 2019 in Current Diabetes Reviews
Verified
Journal Article
Closed access
RNRabia Nabi
Rabia Nabi
Sahir Sultan AlviSahir Sultan Alvi
Sahir Sultan Alvi
Mohd SaeedMohd Saeed
Mohd Saeed
Saheem AhmadSaheem Ahmad
Saheem Ahmad
MKM. Salman Khan
M. Salman Khan
Introduction: Diabetes Mellitus (DM) acts as an absolute mediator of cardiovascular risk, prompting the prolonged occurrence, size and intricacy of atherosclerotic plaques via enhanced Advanced Glycation Endproducts (AGEs) formation. Moreover, hyperglycemia is associated with enhanced glyco-oxidized and oxidized Low-Density Lipoprotein (LDL) possessing greater atherogenicity and decreased the ability to regulate HMG-CoA reductase (HMG-R). Although aminoguanidine (AG) prevents the AGE-induced protein cross-linking due to its anti-glycation potential, it exerts several unusual pharmaco-toxicological effects thus restraining its desirable therapeutic effects. HMG-R inhibitors/statins exhibit a variety of beneficial impacts in addition to the cholesterol-lowering effects. Objective: Inhibition of AGEs interaction with receptor for AGEs (RAGE) and glyco-oxidized-LDL by HMG-R inhibitors could decrease LDL uptake by LDL-receptor (LDL-R), regulate cholesterol synthesis via HMG-R, decrease oxidative and inflammatory stress to improve the diabetes-associated complications. Conclusion: Current article appraises the pathological AGE-RAGE concerns in diabetes and its associated complications, mainly focusing on the phenomenon of both circulatory AGEs and those accumulating in tissues in diabetic nephropathy, diabetic neuropathy, and diabetic retinopathy, discussing the potential protective role of HMG-R inhibitors against diabetic complications.